Filing Flows › Lemaitre Vascular (LMAT) › Q3 2026 › vs Q2 2026
Lemaitre Vascular (LMAT) Q3 2026 vs Q2 2026 (quarter over quarter)
Lemaitre Vascular's revenue fell $2.4M (-3%) from $70.4M in Q2 2026 to $68.0M in Q3 2026. Gross margin 71.7% against 72.1% (-0.5 pts).
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 71.7% | 72.1% | -0.5 pts |
| Operating margin | 26.0% | 29.0% | -2.9 pts |
| Net margin | 22.1% | 24.2% | -2.1 pts |
| Free cash flow margin | 28.9% | 19.4% | +9.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $68.0M | $70.4M | −$2.4M | -3% |
| Gross profit | $48.7M | $50.8M | −$2.1M | -4% |
| Cost of revenue | $19.3M | $19.6M | −$353K | -2% |
| Other income, net | $2.0M | $1.8M | $189K | +11% |
| Operating profit | $17.7M | $20.4M | −$2.7M | -13% |
| Operating expenses | $31.0M | $30.4M | $645K | +2% |
| Pre-tax earnings | $19.7M | $22.2M | −$2.5M | -11% |
| Research & development | $4.4M | $4.8M | −$426K | -9% |
| Sales & marketing | $14.5M | $14.4M | $98K | +0.7% |
| General & admin | $12.1M | $11.1M | $973K | +9% |
| Net earnings | $15.0M | $17.1M | −$2.0M | -12% |
| Income tax | $4.7M | $5.1M | −$489K | -10% |
| Depreciation & amortization | $2.9M | $2.7M | $223K | +8% |
| Share-based compensation | $2.0M | $1.9M | $94K | +5% |
| Working capital & other | $2.1M | −$5.7M | $7.7M | — |
| Operating cash flow | $22.0M | $16.0M | $6.0M | +38% |
| Free cash flow (OCF − capex) | $19.7M | $13.7M | $6.0M | +44% |
| Capital expenditures | $2.3M | $2.3M | $20K | +0.9% |
Questions
How much did Lemaitre Vascular's revenue grow quarter over quarter in Q3 2026?
Lemaitre Vascular's revenue fell $2.4M (-3%) from $70.4M in Q2 2026 to $68.0M in Q3 2026. Gross margin 71.7% against 72.1% (-0.5 pts).